147 related articles for article (PubMed ID: 10225470)
21. Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy measured by non-invasive techniques.
Saenz de la Calzada C; Ziady GM; Hardarson T; Curiel R; Goodwin JF
Br Heart J; 1976 Aug; 38(8):798-803. PubMed ID: 987791
[TBL] [Abstract][Full Text] [Related]
22. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
Adler A; Fourey D; Weissler-Snir A; Hindieh W; Chan RH; Gollob MH; Rakowski H
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28550094
[TBL] [Abstract][Full Text] [Related]
23. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
[TBL] [Abstract][Full Text] [Related]
24. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ; Coons JC
Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
[TBL] [Abstract][Full Text] [Related]
25. Effect of disopyramide on systolic and early diastolic time intervals in patients with hypertrophic cardiomyopathy.
Sumimoto T; Hamada M; Ohtani T; Shigematsu Y; Fujiwara Y; Sekiya M; Hiwada K
J Clin Pharmacol; 1991 May; 31(5):440-3. PubMed ID: 2050829
[TBL] [Abstract][Full Text] [Related]
26. [Left ventricular function at rest and during exercise and the effects of propranolol in patients with hypertrophic cardiomyopathy].
Amano K; Sakamoto T; Sugimoto T
J Cardiol Suppl; 1987; 16():35-51. PubMed ID: 3509682
[TBL] [Abstract][Full Text] [Related]
27. [The effect of some antiarrhythmic drugs on systolic time intervals in normal subjects (author's transl)].
Breithardt G; Jochum E; Kuhn H; Seipel L
Z Kardiol; 1978 Oct; 67(10):6,0-7. PubMed ID: 366939
[TBL] [Abstract][Full Text] [Related]
28. Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy: comparison with diltiazem.
Sumimoto T; Hamada M; Ohtani T; Suzuki M; Abe M; Matsuoka H; Fujiwara Y; Sekiya M; Hiwada K
Cardiovasc Drugs Ther; 1992 Aug; 6(4):425-8. PubMed ID: 1387798
[TBL] [Abstract][Full Text] [Related]
29. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
Sekine T; Daimon M; Hasegawa R; Teramoto K; Kawata T; Tanaka N; Takei Y; Takazawa K; Yoshida K; Komuro I
Heart Vessels; 2006 Nov; 21(6):350-5. PubMed ID: 17143709
[TBL] [Abstract][Full Text] [Related]
30. Combination of disopyramide and propranolol in hypertrophic cardiomyopathy.
Cokkinos DV; Salpeas D; Ioannou NE; Christoulas S
Can J Cardiol; 1989; 5(1):33-6. PubMed ID: 2920304
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
Ogimoto A; Okayama H; Nagai T; Ohtsuka T; Suzuki J; Inoue K; Nishimura K; Saito M; Shigematsu Y; Hamada M; Miki T; Higaki J
J Cardiovasc Pharmacol; 2010 May; 55(5):506-10. PubMed ID: 20179607
[TBL] [Abstract][Full Text] [Related]
32. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
Duncan WJ; Tyrrell MJ; Bharadwaj BB
Can J Cardiol; 1991 Mar; 7(2):81-6. PubMed ID: 2049687
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of sinoatrial conduction time with therapeutic doses of antiarrhythmic agents in isolated cross-perfused canine atria.
Shimotori M; Kobayashi M; Chiba S
Jpn Heart J; 1985 Jan; 26(1):113-22. PubMed ID: 4009954
[TBL] [Abstract][Full Text] [Related]
34. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
Hulting J; Rosenhamer G
J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
[No Abstract] [Full Text] [Related]
35. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.
Pernat A; Pohar B; Horvat M
J Electrocardiol; 1997 Oct; 30(4):341-4. PubMed ID: 9375912
[TBL] [Abstract][Full Text] [Related]
36. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
[TBL] [Abstract][Full Text] [Related]
37. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Hamada M; Shigematsu Y; Hara Y; Suzuki M; Ohtsuka T; Hiasa G; Ogimoto A; Saeki H; Suzuki J; Hiwada K
Jpn Circ J; 2001 Jun; 65(6):531-8. PubMed ID: 11407736
[TBL] [Abstract][Full Text] [Related]
38. [The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].
Angermann C; Autenrieth G
Klin Wochenschr; 1981 Jul; 59(14):803-11. PubMed ID: 7265814
[TBL] [Abstract][Full Text] [Related]
39. The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men.
Cathcart-Rake WF; Coker JE; Atkins FL; Huffman DH; Hassanein KM; Shen DD; Azarnoff DL
Circulation; 1980 May; 61(5):938-45. PubMed ID: 7363436
[TBL] [Abstract][Full Text] [Related]
40. Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation.
Gondo N; Kumagai K; Yamanouchi Y; Annoura M; Saku K
J Cardiol; 2000 Dec; 36(6):405-10. PubMed ID: 11190584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
